Journals / Turkish Journal of Gastroenterology / 2011 / Cilt: 22 - Sayı: 3

Kronik hepatit B ve D hastalarında ileri fibrozis belirleyicileri olarak serum bağ doku belirteçleri

Serum connective tissue markers as predictors of advanced fibrosis in patients with chronic hepatitis B and D

Pages
305–314
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In conclusion, advanced liver fibrosis in chronic hepatitis B and D may be predicted with use of these two fibrosis markers.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aims: Liver biopsy to assess fibrosis is invasive and prone to sampling error.
📊
Key Findings & Data:Methods: We therefore determined 9 serum fibrosis markers, liver biochemical tests and ultrasound parameters in 109 consecutive adult patients with chronic hepatitis B and D.
💡
Conclusion & Impact:Conclusion: In conclusion, advanced liver fibrosis in chronic hepatitis B and D may be predicted with use of these two fibrosis markers.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aims: Liver biopsy to assess fibrosis is invasive and prone to sampling error. While algorithms of serum markers to predict fibrosis stage have been described for chronic hepatitis C, these cannot be applied equally well to hepatitis B. Methods: We therefore determined 9 serum fibrosis markers, liver biochemical tests and ultrasound parameters in 109 consecutive adult patients with chronic hepatitis B and D. All patients had compensated liver disease. Using the METAVIR score, advanced disease was defined as fibrosis stage &#8805;F2, and active inflammation as grade &#8805;A2. A gold standard was created considering splenomegaly and/or platelets <150,000 as indicators of advanced fibrosis irrespective of histology. Area under receiver operating characteristics curves was used for assessment of single markers and odds ratio for their combinations. Results: Patients with advanced disease were older, had lower albumin, higher gamma glutamyl transferase and lower platelet. Levels of 6 of the 9 fibrosis markers, tissue inhibitor of metalloproteinases-1, procollagen type III aminoterminal propeptide, matrix metalloproteinase- 2, laminin, hyaluronan and collagen IV correlated with advanced fibrosis. Markers useful for fibrosis prediction also predicted marked inflammation. Using the gold standard, age, prothrombin time, gamma glutamyl transferase and albumin were independent predictors of fibrosis with odds ratio&#8217;s of 3.11, 4.18, 3.35 and 5.25, respectively. Their combined use predicted fibrosis with an odds ratio of 228.8. Tissue inhibitor of metalloproteinases-1 and hyaluronan were powerful predictors of fibrosis (Odds ratio&#8217;s of 8.65 and 8.38). Their combined use revealed an odds ratio of 28.6, when compared with the gold standard. Conclusion: In conclusion, advanced liver fibrosis in chronic hepatitis B and D may be predicted with use of these two fibrosis markers.

Özet

Amaç: Karaciğer fibrozisinin biyopsi ile değerlendirilmesi invaziv bir yöntemdir ve örnekleme hatasına yol açabilir. Fibrozis evresini öngören serum fibrozis belirteç algoritmaları kronik hepatit C’de tanımlanmış olmasına rağmen, kronik hepatit B’de benzer şekilde uygulanmamıştır. Yöntem: Bu amaçla 9 serum fibrozis belirteci, karaciğer biyokimyasal testleri ve ultrasonografik parametreleri, ardışık olarak 109 yetişkin kronik hepatit B ve D hastasında değerlendirdik. Tüm hastalar kompanse karaciğer hastalığına sahipti. METAV‹R skoru ile evre ≥2 fibrozis ve grade ≥2 inflamasyon varlığı ileri karaciğer hastalığı olarak tanımlandı. Splenomegali ve/veya 150,000 altında trombosit sayısı- nın, histolojiden bağımsız olarak, ileri fibrozisin belirleyicisi olduğu hesaba katılarak altın standart yapılmaya çalışıldı. Belirteçlerin ve bunları n kombinasyonlarının Odds oranlarının değerlendirilmesinde ROC eğrisinin altında kalan alan (AUROC) hesaplaması kullanıldı. Bulgular: İleri hastalığı olanlar daha ileri yaşlıydı, daha düşük albumin, daha yüksek gama glutamil transferaz ve daha düşük platelet sayı sına sahipti. Dokuz fibrozis belirtecinin 6’sının seviyesi (metalloproteinazlar-1 doku inhibitörü, prokollagen tip III aminoterminal propeptide, matriks metalloproteinaz, laminin, hyaluronan and kollagen IV) ileri fibrozis ile korele idi. Bu altı belirteç ayrıca inflamasyonun tahmininde de faydalıydı. Altın standart kullanımıyla, yaş, protrombin zamanı, gama glutamil transferaz ve albumin sırasıyla 3.11, 4.18, 3.35 ve 5.25 odds oranları ile fibrozisin bağımsız belirleyicisiydi. Bunların kombinasyonu odds oranı 228.8 ile fibrozisi öngördü. Metalloproteinaz- 1 doku inhibitörü ve hyaluronan fibrozisin güçlü belirleyicileriydi (odds oranı 8.65 ve 8.38, sırayla). Altın standart ile karşılaştırıldığında, bu ikisinin kombinasyonunda odds oranı 28.6 idi. Sonuç: Sonuç olarak, kronik hepatit B ve D’de ileri karaciğer fibrozisi, bu iki fibrozis belirtecinin kullanımı ile doğru olarak öngörülebilir.

🔖

Cite This Article

SEVEN, G., KARATAYLI, S. C., KÖSE, S. K., YAKUT, M., KABAÇAM, G., TÖRÜNER, M., HEPER, O. A., VOELKER, M., ERDEN, E., BOZDAYI, A. M., UZUNALİMOĞLU, Ö., BOZKAYA, H., YURDAYDIN, C., SCHUPPAN, D. (2011). Kronik hepatit B ve D hastalarında ileri fibrozis belirleyicileri olarak serum bağ doku belirteçleri. Turkish Journal of Gastroenterology, Cilt: 22 - Sayı: 3, 305–314. https://ajindex.com/articles/410353

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Lok ASF, Heathcote EJ, Hoofnagle JH. Management of hepatitis B, 2000: summary of a workshop. Gastroenterology 2001; 120: 1828-53
  2. Heathcote J. Antiviral therapy for patients with chronic hepatitis C. Semin Liver Dis 2000; 20: 185-99
  3. Nord JH. Biopsy diagnosis of cirrhosis: blind percutaneous versus guided direct vision techniques. A review. Gastrointest Endosc 1982; 28: 102-4
  4. Abdi W, Millan JC, Mezey E. Sampling variability on percutaneous liver biopsy. Arch Intern Med 1974; 139: 667-9
  5. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-8
  6. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57
  7. Colombo M, Del Ninno E, De Franchis R, et al. Ultrasoundassisted percutaneous liver biopsy: superiority of the Trucut over the Menghini needle for diagnosis of cirrhosis. Gastroenterology 1988; 95: 487-9
  8. Pinzani M. The ELF panel: a new crystal ball in hepatology? Gut 2010; 59: 1165-7
  9. Rohde H, Vargas L, Hahn E, et al. Radioimmunoassay for type III procollagen peptide and its application to human liver disease. Eur J Clin Invest 1979; 9: 451-9
  10. Schuppan D, Stölzel U, Oesterling C, Somasundaram R. Serum assays for liver fibrosis. J Hepatol 1995; 22(Suppl): 82-8
  11. Poynard T, Aubert A, Bedossa P, et al. A simple biological index for detection of alcoholic liver disease in drinkers. Gastroenterology 1991; 100: 1397-402
  12. Naveau S, Poynard T, Benattar C, et al. Alpha-1-macroglobulin and hepatic fibrosis: diagnostic interest. Dig Dis Sci 1994; 11: 2426-32
  13. Poynard T, Bedossa P. Age and platelet count: a simple index for predicting the presence of histologic lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepat 1997; 4: 199-208
  14. Imbert-Bismut F, Ratziu V, Pieroni L, et al., for the MULTIVIRC group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-75
  15. Forns X, Ampurdanès S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-92
  16. Kaul V, Friedenberg FK, Braitman LE, et al. Development and validation of a model to diagnose cirrhosis in patients with hepatitis C. Am J Gastroenterol 2002; 97: 2623-8